An Independent Asset Review (IAR) is an external, objective assessment used to evaluate the value, risks, and readiness of an asset such as a program, platform, portfolio, or operational capability.
In clinical development environments, IARs may assess trial infrastructure, operational maturity, compliance posture, or portfolio viability for investment and governance decisions. Findings can influence resource allocation, vendor strategy, and risk mitigation planning for ongoing or planned studies. Independent review strengthens transparency and executive decision-making. Although indirect, IAR outcomes can materially affect trial execution capability and compliance readiness.